A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy
Biochemical Pharmacology · 2026-12 · 254 · 118591
DOI: 10.1016/j.bcp.2026.118591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-12. Verfasst von Yogalakshmi Sabapathy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute (WIA), Chennai, India. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
Ewing sarcoma (ES) is an aggressive paediatric malignancy characterised by high CD99 expression and limited targeted therapeutic options. In this study, we developed a recombinant anti-CD99 Cancer Institute Antibody (CIAb-anti-CD99) by isotype switching a hybridoma-derived IgM/κ antibody to an IgG2a/κ format to improve manufacturability and therapeutic applicability. Recombinant CIAb-anti-CD99 was expressed in CHO-K1 cells and retained specific recognition of CD99, as demonstrated by immunofluorescence, flow cytometry, Western blotting, and immunohistochemistry. Functionally, CIAb-anti-CD99 increased the Annexin V/PI-positive cell population and inhibited proliferation and clonogenic growth of CD99-positive ES cells in vitro. To evaluate the potential of CIAb-anti-CD99 for targeted drug delivery, CIAb-anti-CD99 was conjugated to doxorubicin to generate a CD99-targeted antibody-drug conjugate (CIAb-Dox). In vivo biodistribution studies demonstrated tumour localisation and prolonged retention of CIAb-anti-CD99 in A673 xenograft tumours. Therapeutic evaluation in an A673 cell line-derived xenograft (CDX) model showed that CIAb-Dox significantly suppressed tumour growth compared with vehicle and antibody monotherapy. Histopathological analysis demonstrated lower viable tumour content and greater tumour necrosis in CIAb-Dox-treated tumours. Quantitative immunohistochemical analysis further showed a significant reduction in the Ki67-positive proliferative index and increased cleaved PARP staining, consistent with apoptosis-associated cellular changes. CIAb-Dox demonstrated enhanced antitumour activity while maintaining a favourable tolerability profile. Collectively, these findings provide preclinical evidence supporting further investigation of CD99-directed antibody-drug conjugates. CIAb-anti-CD99 represents a functionally active CD99-targeting antibody, while CIAb-Dox warrants further evaluation in additional Ewing sarcoma models, together with mechanistic, pharmacokinetic, and comprehensive analytical studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Institute (WIA), Chennai, India.
- Cancer Institute (WIA), Chennai, India. Electronic address: r.balaji@cancerinstitutewia.org.
- Indian Institute of Technology Madras, Chennai, India.
- Tamil Nadu Veterinary and Animal Sciences University, Chennai, India.
- Cancer Institute (WIA), Chennai, India. Electronic address: ggopisetty@gmail.com.
Förderung
- Science and Engineering Research Board
Zitieren
APA
Sabapathy, Y., Ramachandran, B., Ramanathan, P., Sundersingh, S., Yasin, N., Madaboosi, N., Jayaraman, G., Natesan, P., Gopisetty, G., & Thangarajan, R. (2026). A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy. Biochemical Pharmacology, 254, 118591. https://doi.org/10.1016/j.bcp.2026.118591
Vancouver
Sabapathy Y, Ramachandran B, Ramanathan P, Sundersingh S, Yasin N, Madaboosi N, et al. A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy. Biochemical Pharmacology. 2026;254:118591. doi:10.1016/j.bcp.2026.118591
BibTeX
@article{Sabapathy2026,
author = {Sabapathy, Yogalakshmi and Ramachandran, Balaji and Ramanathan, Priya and Sundersingh, Shirley and Yasin, Nazeer and Madaboosi, Narayanan and Jayaraman, Guhan and Natesan, Pazhanivel and Gopisetty, Gopal and Thangarajan, Rajkumar},
title = {A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {254},
pages = {118591},
doi = {10.1016/j.bcp.2026.118591}
}
EUVIMED